Faron Pharmaceuticals Oy of Finland has announced its intention to float on the AIM market in London in order to raise money for a Phase 3 trial of its agent for acute respiratory distress syndrome Traumakine, a recombinant human interferon beta-1a. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
